Welcome to our dedicated page for Immunic SEC filings (Ticker: IMUX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Immunic, Inc. (IMUX) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission. As a Nasdaq-listed biotechnology issuer, Immunic uses filings such as Forms 10-K, 10-Q, and 8-K to report on its financial condition, clinical development progress, capital structure, and material corporate events.
Current reports on Form 8-K are particularly relevant for tracking Immunic’s milestones. Recent 8-K filings reference press releases on quarterly financial results and corporate updates, including spending on research and development for vidofludimus calcium (IMU-838) and other programs, as well as financings such as registered direct offerings and underwritten public offerings. Other 8-Ks describe presentation of new multiple sclerosis data at major scientific meetings and provide details on items like stock appreciation rights grants and Nasdaq listing notices regarding minimum bid price requirements.
Investors can also use SEC filings to monitor liquidity and risk disclosures, where Immunic discusses its cash and cash equivalents, the need to raise additional capital to fund operations, and the implications of financing structures. Filings may further elaborate on the company’s intellectual property strategy for vidofludimus calcium and other pipeline assets, complementing information in press releases.
On Stock Titan, these documents are supplemented with AI-powered summaries that explain key points in accessible language, helping readers quickly understand the significance of lengthy filings. Real-time updates from EDGAR ensure that new IMUX filings, including 10-Q and 10-K reports and any Form 4 insider transaction disclosures when available, are added promptly so users can review changes in ownership, compensation-related grants, and other governance matters alongside Immunic’s clinical and financial reporting.
683 Capital Management, LLC, 683 Capital Partners, LP and Ari Zweiman (collectively the Reporting Persons) report beneficial ownership of warrants exercisable into 10,634,446 shares of Immunic, Inc. common stock. Those exercisable warrants, as disclosed, represent approximately 9.9% of the company's common stock on a diluted basis as presented in the filing. The reported position reflects shared voting and shared dispositive power over the warrants rather than sole control.
The percentage is calculated using the issuer's disclosed outstanding share base together with the maximum shares issuable upon exercise, and the warrants include a 9.99% beneficial ownership limitation that caps potential holdings.
Aberdeen Group plc and its U.S. subsidiary abrdn Inc filed a Schedule 13G on 31 Jul 2025 reporting passive ownership of Immunic, Inc. (IMUX) common stock as of 30 Jun 2025.
- Shares held: 8,243,941
- Ownership: 8.603 % of outstanding shares
- Voting power: 0 sole / 8,243,941 shared
- Dispositive power: 0 sole / 8,243,941 shared
- Filing basis: Rule 13d-1(b); abrdn Inc classified as Investment Adviser (IA, CO) and Aberdeen Group plc as Parent Holding Company (HC)
The institutions certify the stake is held in the ordinary course of business with no intent to influence control. Crossing the 5 % threshold adds a significant global asset manager to IMUX’s shareholder base, potentially enhancing liquidity and investor confidence.
Immunic (Nasdaq: IMUX) disclosed that it received a Nasdaq bid-price deficiency notice after its shares closed below $1.00 for 30 consecutive trading days, violating Listing Rule 5450(a)(1).
The company has 180 calendar days, until December 24 2025, to regain compliance by posting a closing bid of at least $1.00 for ten consecutive business days. If unsuccessful, Immunic may seek a second grace period or effect a reverse stock split; failure would result in delisting.
The notice does not immediately affect the stock’s listing on the Nasdaq Global Select Market. Management is monitoring the price and evaluating options.
This Form 4/A amends a previously filed Form 4 for Jason Tardio, President and COO of Immunic (IMUX), correcting an administrative error in reported stock option grants from June 5, 2025.
Key transactions reported:
- Purchase of 12,512 shares of common stock at $0.79 per share
- Grant of 598,500 stock options at an exercise price of $0.7729, expiring June 5, 2035
The stock options vest over 4 years, with 25% vesting after one year and the remainder vesting monthly over the following 36 months. This amendment corrects the number of stock options originally reported in the June 9, 2025 filing.
Immunic CFO Glenn Whaley filed an amended Form 4 (Form 4/A) to correct a previously reported stock option grant from June 5, 2025. The amendment addresses an administrative error in the number of options reported in the original filing dated June 9, 2025.
Key details of the corrected transaction:
- Granted 503,500 stock options at an exercise price of $0.7729 per share
- Options expire on June 5, 2035
- Vesting schedule: 25% vests after one year, with remaining vesting monthly over 36 months
The direct ownership of these derivative securities provides long-term equity incentive alignment between the CFO and shareholders. The relatively low exercise price suggests the company's stock may be trading at modest levels, though this grant represents a significant equity position for a C-level executive.
Immunic CEO Daniel Vitt filed an amended Form 4 on June 28, 2025, correcting a previously filed Form 4 from June 6, 2025. The amendment addresses two significant transactions:
- Stock Purchase: Acquired 15,000 shares of common stock at $0.77 per share on June 4, 2025, bringing direct ownership to 29,000 shares
- Stock Option Grant: Received 1,558,000 stock options on June 5, 2025, with an exercise price of $0.7729, expiring June 5, 2035
The options vest 25% after one year, with remaining shares vesting monthly over 36 months. Vitt also maintains indirect ownership of 362,877 shares through Listrax UG, where he serves as Managing Director. The amendment specifically corrects an administrative error regarding the number of stock options granted in the original filing.
FAQ
What is the current stock price of Immunic (IMUX)?
What is the market cap of Immunic (IMUX)?
